ViroMed of Korea Receives US Fast Track Status for Gene Therapy

Korea's ViroMed was granted Fast Track designation by the US FDA for VM202, a novel gene therapy scheduled to begin a US Phase II trial. VM202, ViroMed's lead drug candidate, will be tested in patients with Amyotrophic Lateral Sclerosis. In January, ViroMed published positive results from a US-Korea Phase II trial of VM202 in patients with critical limb ischemia. ViroMed said it would release data from a completed Phase I/II trial of VM202 in ALS patients later this year. More details.... Stock Symbol: (KOSDAQ:084990) Share this with colleagues: // //